14th GAVI BOARD MEETING
Abuja, Nigeria, 4-5 December 2004
SUMMARY REPORT

>>Back to the 14th GAVI Board Meeting

4 ADIP Management Committee Report and Recommendations

• The rotavirus vaccines now being tested are being analyzed as to whether they will protect against the strains that are prevalent in developing countries. Current evidence indicates that they might provide this ‘cross-protection’.
• New information from the United States indicates that the pneumococcal vaccine now being provided there to infants is having a substantial ‘herd-immunity’ effect – protecting non-vaccinated population against disease.
• There was a debate as to whether UNICEF should automatically be responsible for all procurement activities for GAVI, including all negotiations with industry. Some members felt that existing systems should be used, while others felt that future decisions should be based on the competitive merit of different options.
• Given that some issues pertaining to vaccines under development may differ from those pertaining to existing vaccines, different procurement strategies might be required for new vaccines. It was noted that this will be taken up by the UNICEF – Gates Foundation review of procurement strategies due to be presented to the July Board with an interim report to the April Board.

DECISIONS
The Board:

4.1 Adopted the ADIP 2005 budgets:

4.1.1 Rotavirus ADIP: $11,035,594;

4.1.2 Pneumococcal ADIP: $8,752,909.

4.2 Adopted the terms of reference for the Rotavirus Vaccine Supply Working Group, with the following adjustments:

4.2.1 Its composition should be revised to include a donor representative.

4.2.2 It should outline precisely the strategy for supply of rotavirus vaccines including pricing policy, and the role of UNICEF, and provide justification for why that strategy is being used. This strategy could then feed into the work being done on the long-term procurement strategy.

4.2.3 Procurement could ultimately be the responsibility of UNICEF.

>>Back to the 14th GAVI Board Meeting